Fibrosis, Chronic Liver Disease
Conditions
Keywords
hepatitis C virus infection, chronic liver disease, fibrosis-related cytokine
Brief summary
Hepatitis C virus (HCV) infection causes different disease spectrum ranging from minimal progressive liver disease to cirrhosis or hepatocellular carcinoma. Evidence indicates that host genetic factor may play a role in determining disease progression. It is known that many cytokine polymorphisms affect disease progressin via increasing hepatic fibrosis that are key factors in progressing liver injury. By combinations of fibrosis-relating gene polymorphisms, this study aims to identify patients with high risk for progressive liver disease. These patients need intensive therapy to decrease morbidity and mortality of chronic HCV-related liver disease.
Detailed description
Determination of the following fibrosis-relating gene polymorphisms in HCV-related chronic liver disease and HCC will be performed: TNF-α , TNF-β, Factor V Leiden, TGF-β1, PDGF-B gene, Angiotensinogen (AT),Angiotensin converting enzyme (ACE), microsomal epoxide hydrolase (mEH) and glutathione-S-transferase (GST).
Interventions
polymorphisms of fibrosis-relating cytokine were measured to validate the effectiveness of fibrosis in HCV-related chronic liver disease
Fibrosis-relating cytokine polymorphisms in hepatitis C virus-related chronic liver disease were measured to validate the degree of fibrosis
fibrosis-relating cytokine polymorphism
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients with anti-HCV positive
Exclusion criteria
* Anti-HCV-negative patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cytokine gene polymorphism on disease severity | years |
Countries
Taiwan